Clinical Trial Update: Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bortezomib with pegylated liposomal doxorubicin in BRCA wild-type platinum-resistant recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Carcinoma
• Ovarian Neoplasm

Drugs mentioned

• Bortezomib (bortezomib)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Ovarian Neoplasm Epithelial, High Grade Serous Carcinoma | Phase 2 | Status: UNKNOWN